Skip to main content

Zynyz Disease Interactions

There are 4 disease interactions with Zynyz (retifanlimab).

Moderate

PD-1/PD-L1 inhibitors (applies to Zynyz) HSCT

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Transplantation

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.

Switch to professional interaction data

Moderate

PD-1/PD-L1 inhibitors (applies to Zynyz) myasthenia gravis

Moderate Potential Hazard, Moderate plausibility.

Myasthenic syndrome/myasthenia gravis (including exacerbation) has been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients with myasthenia gravis.

Switch to professional interaction data

Moderate

PD-1/PD-L1 inhibitors (applies to Zynyz) organ transplant

Moderate Potential Hazard, Moderate plausibility.

Solid organ transplant rejection and other transplant (including corneal graft) rejection have been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ or other transplant.

Switch to professional interaction data

Moderate

Retifanlimab (applies to Zynyz) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

No dose adjustment of retifanlimab is recommended for patients with mild hepatic impairment. No clinical studies were conducted with retifanlimab in patients with moderate to severe hepatic impairment. Retifanlimab can cause immune-mediated hepatitis. Monitor liver enzymes at baseline and periodically during treatment. Use caution in patients with hepatic impairment.

Switch to professional interaction data

Zynyz drug interactions

There are 557 drug interactions with Zynyz (retifanlimab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer